Lydia Vela-Desojo
Overview
Explore the profile of Lydia Vela-Desojo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westenberger A, Skrahina V, Usnich T, Beetz C, Vollstedt E, Laabs B, et al.
Brain
. 2024 Aug;
147(8):2652-2667.
PMID: 39087914
Estimates of the spectrum and frequency of pathogenic variants in Parkinson's disease (PD) in different populations are currently limited and biased. Furthermore, although therapeutic modification of several genetic targets has...
2.
Delgado C, Lopez-Jimenez A, Lopez-Valdes E, Gomez-Mayordomo V, Baltasar-Corral A, Martinez-Castrillo J, et al.
Parkinsonism Relat Disord
. 2023 Aug;
114:105776.
PMID: 37544162
No abstract available.
3.
Mata-Marin D, Pineda-Pardo J, Michiels M, Pagge C, Ammann C, Martinez-Fernandez R, et al.
Psychiatry Clin Neurosci
. 2022 Dec;
77(4):223-232.
PMID: 36579893
Aim: Impulse-control disorder is a common neuropsychiatric complication in Parkinson's disease (PD) under dopamine replacement therapy. Prior studies tested the balance between enhanced desire towards reward and cognitive control deficits,...
4.
Manez-Miro J, Vivancos-Matellano F, Alonso-Frech F, Vela-Desojo L, Lopez-Ariztegui N, Lopez-Manzanares L, et al.
Mov Disord Clin Pract
. 2022 Nov;
9(8):1085-1093.
PMID: 36339297
Background: Dopamine replacement therapy reduces most motor and nonmotor features of Parkinson's disease. However, with disease progression, adjustments of dopaminergics and the application of advanced therapies must be considered. Objectives:...
5.
Kovacs N, Szasz J, Vela-Desojo L, Svenningsson P, Femia S, Parra J, et al.
Parkinsonism Relat Disord
. 2022 Aug;
105:139-144.
PMID: 36008198
Introduction: Patients with advanced Parkinson's disease (APD) commonly experience motor and nonmotor symptoms (NMS) associated with functional limitations and decreased quality of life. We compared motor and nonmotor outcomes in...
6.
Guerra-Hiraldo J, Lopez-Jimenez A, Gasca-Salas C, Maycas-Cepeda T, Gomez-Sanchez P, Lopez-Manzanares L, et al.
J Neurol
. 2022 Aug;
270(1):548-551.
PMID: 35925399
No abstract available.
7.
Dileone M, Ammann C, Catanzaro V, Pagge C, Piredda R, Monje M, et al.
Brain Stimul
. 2022 May;
15(3):857-860.
PMID: 35609815
No abstract available.
8.
Vela-Desojo L, Urso D, Osuna-Lopez M, Hoenicka J
J Clin Med
. 2022 Mar;
11(6).
PMID: 35329915
-dystonia-parkinsonism (PLAN-DP) is characterized by levodopa responsive parkinsonism and dystonia. While neuropsychiatric symptoms and early cognitive decline are also common in this entity there is little information regarding other non-motor...
9.
Monje M, Sanchez-Ferro A, Pineda-Pardo J, Vela-Desojo L, Alonso-Frech F, Obeso J
Mov Disord
. 2021 Aug;
36(8):1994-1995.
PMID: 34409687
No abstract available.
10.
Fasano A, Gurevich T, Jech R, Kovacs N, Svenningsson P, Szasz J, et al.
Mov Disord
. 2021 Apr;
36(8):1853-1862.
PMID: 33908647
Background: Levodopa-carbidopa intestinal gel (LCIG) is administered directly to the small intestine of patients with advanced Parkinson's disease (APD) to help maintain stable plasma levodopa levels. Objective: The objective of...